Analysts Have Conflicting Sentiments on These Healthcare Companies: TransMedics Group (TMDX), Regeneron (REGN) and Tarsus Pharmaceuticals (TARS)
Analysts updated ratings for healthcare companies. TD Cowen maintained a Buy rating on TransMedics Group (TMDX) with a $120 target. Regeneron (REGN) was kept at Hold by Leerink Partners. Oppenheimer maintained a Buy rating on Tarsus Pharmaceuticals (TARS) with a $100 target. All have consensus ratings and price targets.
How this was made
The 30-second read
Why it matters
Analyst maintenance with target adjustments offers modest directional cues but lacks strong catalyst.
Market read
Provides modest guidance for investors; limited immediate trading impact.
What to watch
Upcoming earnings releases could override current analyst targets.
Background
The article aggregates analyst rating updates for three healthcare companies, providing new price targets but no rating changes.
Ticker impact
Analyst Josh Jennings maintained a Buy rating and set a $120 price target for TransMedics Group.
potential modest upside as investors price in higher target
Rating unchanged but target raised suggests confidence in upside.
Analyst David Risinger maintained a Hold rating and RBC Capital kept a Hold with a $737 price target for Regeneron.
likely limited pressure as market sees no change
No rating upgrade or target lift, so price action expected to be muted.
Oppenheimer analyst Mazahir Alimohamed maintained a Buy rating and set a $100 price target for Tarsus Pharmaceuticals.
possible slight upside as target exceeds current price
Target increase signals confidence, but rating unchanged.
Market effects
Analyst coverage may slightly lift healthcare sector sentiment.
U.S. market focus; limited regional effect.
Minimal global impact.
Counterpoint
Ratings unchanged; investors may wait for earnings before acting.
Key entities
- companyTransMedics Group
Medical device company
- companyRegeneron
Biopharmaceutical company
- companyTarsus Pharmaceuticals
Biopharma focused on rare diseases
